Many patients with Parkinson's disease experience periods during the day of "OFF" episodes, or worsening of symptoms.
What do rapidly changing technologies mean to the collection of stated-preference studies – studies that ask individuals what they value in their health and health care?
Insights from our experiences developing medical product dossiers, with key considerations for manufacturers planning to develop early dossiers for their products.
For the fifth straight year, Forbes has included RTI in its list of America’s Best Midsize Employers
MINERVA project (Metadata for data discoverability and study replicability in observational studies) is launched
"I am honored to serve on the ENCePP Steering Committee on behalf of research centers in Europe."
The US Food and Drug Administration (FDA) is no longer requiring a black box warning on the label for the drug FORTEO® (teriparatide) and has released the drug’s sponsor from its post-market commitments. These moves were based on results from 18 years of epidemiologic research conducted by...
Please join Xabier Garcia de Albeniz for this recorded 30-minute case-study workshop on the use of causal inference methods for real-world evidence.
Launch of the SIGMA Consortium heralds a new era of collaboration to better understand safety and effectiveness of medical interventions.
In 2019, the US Department of Health and Human Services (HHS) announced the “Ending the HIV Epidemic: A Plan for America” initiative. As part of that initiative, CDC, RTI Health Solutions (RTI-HS), and RTI International researchers performed a study on allocating funds for HIV prevention to...
HTAi symposium highlights - value assessment in Alzheimer's disease research should incorporate the breadth of relevant outcomes
Antibiotics have played a significant role in expanding life expectancy over the last 100 years. However, bacteria have evolved and developed the genetic machinery to adapt and resist antimicrobials, threatening to make antibiotics ineffective – known as antimicrobial resistance (AMR). The...
it also explains Markov and Budget Impact Analysis modeling and discusses the advantages and disadvantages of using retrospective databases and real-world data
RTI Health Solutions (RTI-HS) is pleased to announce that we are a certified facilitator for the Medtech Early Technical Assessment (META) tool developed by the National Institute for Health and Care Excellence (NICE). META is an online platform designed to provide a budget-friendly value...
A first-time study determined that just 30.6% of US 17-year-olds had received all vaccines
RTI Health Solutions is pleased to announce that Brett Hauber, PhD, Senior Economist and VP, Health Preference Assessment, has been appointed as Senior Fellow in the RTI Fellow Program.
We're excited to reach this milestone in our journey
RTI Health Solutions (RTI-HS) is proud to announce that two of our researchers have been awarded fellowship status by the International Society for Pharmacoepidemiology (ISPE) Board of Directors. Both Alicia Gilsenan, PhD, RPh, and Andrea Margulis, MD, ScD, will be acknowledged as new FISPE...
On August 31, 2020, the FDA released its draft guidance titled “Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation.”
The Author Awards Program, now in its 17th year, was established by the RTI Fellows as a way to recognize staff members
In advance of an approved COVID-19 vaccine, the European Medicines Agency (EMA) has commissioned research to monitor any vaccine that is approved for its safety and effectiveness in clinical practice.
Multiple myeloma (MM) is a type of blood cancer that occurs in our body’s plasma cells. Rapidly reproducing, cancerous cells collect in bone marrow and crowd out healthy cells. Myeloma cells produce antibodies that, instead of fighting off infection, cause problems such as kidney and bone damage...
Many biologic treatments are available for controlling symptoms of psoriasis. The treatments have varying purchase costs, dosing amounts and frequency, and real-world use. Therefore, understanding the total costs of these treatments to insurers can be difficult.
Experts on our Patient-Centered Outcomes Assessment (PCOA) team collaborated to create this best practices document to help research teams mitigate some of the impacts of COVID-19 on the collection and use of clinical outcome assessment (COA) data.